Paasa Logo
Intellia Therapeutics, Inc. logo
NTLANASDAQMarket openCloses 4:00pm ET

Intellia Therapeutics, Inc.

$11.77Last updated
-$0.39 (3.24%)Past day
Timezone

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is trading at $11.77, about ₹1,130 at today's USD/INR rate, as of 25 Sep 2026, 2:16 PM ET, down 3.24% today. Indian residents can buy Intellia Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$12.27
Previous close:$12.16
Volume:1.89M

Today's low

$11.66

Today's high

$12.28

52 week low

$7.95

52 week high

$28.25

NTLA opened at $12.27, closed previously at $12.16, and has traded between $7.95 and $28.25 over the past 52 weeks.

About

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.

Country
US
CEO
John Leonard
Exchange listed on
NASDAQ
Industry
Biotechnology
Base currency
USD
Full Time Employees
377
Sector
Healthcare
IPO date
06/05/2016

Key statistics

Avg. volume

4.83M

Market cap

$1.64B

P/E Ratio

-3.50

Price-to-sales ratio

27.62

Enterprise value

$1.61B

Free cash flow yield

-28.36%

Debt-to-equity ratio

0.10

Return on equity

-57.79%

ROIC

-52.86%

Beta

1.82

Dividend yield

0.00%

Last dividend

$0.00

Financial overview

Revenue

$67.67M

Earnings per share

-$3.81

Free cash flow

-$354.66M

Net profit margin

-672.16%

Gross margin

-46.48%

EBITDA

-$396.77M

Revenue growth

16.92%

Similar securities

This is not an investment recommendation

How to buy Intellia Therapeutics from India

Indian residents can buy Intellia Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for Intellia Therapeutics and place an order

    Find Intellia Therapeutics by name or by its ticker, NTLA, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Intellia Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Intellia Therapeutics position in USD and INR. Intellia Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Intellia Therapeutics from India

Trading and taxes when buying Intellia Therapeutics from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneIntellia Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
US estate tax
May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy Intellia Therapeutics stock?

Yes. Intellia Therapeutics (NTLA) has been listed on NASDAQ since 2016, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one Intellia Therapeutics share cost in rupees?

One Intellia Therapeutics share is $11.77 — about ₹1,130 at a USD/INR rate of 96.02 on 24 Sep 2026. Both the Intellia Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Intellia Therapeutics from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy whole shares of Intellia Therapeutics?

Yes. One Intellia Therapeutics share is $11.77, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Intellia Therapeutics.

How are gains on Intellia Therapeutics shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Intellia Therapeutics price. Paasa issues a capital-gains statement for your return.

Does Intellia Therapeutics pay a dividend?

No. Intellia Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Intellia Therapeutics from India?

NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is there estate or inheritance tax on Intellia Therapeutics shares held from India?

US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.

Do I have to declare Intellia Therapeutics shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Intellia Therapeutics holding, its cost and its closing value.

How do I sell Intellia Therapeutics and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.